Alnylam Pharmaceuticals Inc. suspended dosing in ongoing studies of fitusiran following the report of a fatal thrombotic event in a patient with hemophilia A without inhibitors that occurred during the therapy's phase II open-label extension (OLE) study. In July, the antithrombin-targeting RNAi therapy developed by Alnylam with partner Sanofi Genzyme, entered phase III territory with the launch of the three-part ATLAS program in hemophilia A and B. (See BioWorld, July 10, 2017.)